Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy [Melanoma]

Conclusion
No survival benefit for adjuvant HDI in patients with a single positive SLN was found. Among patients with tumor-negative SLN by conventional pathology but with melanoma detected in the SLN by RT-PCR, there was no OS benefit for CLND or CLND+HDI.

Source: Journal of Clinical Oncology - March 22, 2016 Category: Cancer & Oncology Authors: McMasters, Egger, Edwards, Ross, Reintgen, Noyes, Martin, Goydos, Beitsch, Urist, Ariyan, Sussman, Davidson, Gershenwald, Hagendoorn, Stromberg, Scoggins Tags: Surgery, Chemotherapy Melanoma Source Type: research